Bio-Techne Corp (TECH) Getting Somewhat Favorable Press Coverage, Analysis Finds
Media stories about Bio-Techne Corp (NASDAQ:TECH) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Techne Corp earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.0431467725452 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Brokerages Anticipate Bio-Techne Corp (TECH) Will Post Quarterly Sales of $142.75 Million (americanbankingnews.com)
- Bio-Techne Corp (TECH) Upgraded by BidaskClub to Buy (americanbankingnews.com)
- Bio-Techne Corp to Post FY2019 Earnings of $3.99 Per Share, William Blair Forecasts (TECH) (americanbankingnews.com)
- Bio-Techne To Present At The Baird 2017 Global Healthcare Confer – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Bio Techne : To Present At The Baird 2017 Global Healthcare Conference (4-traders.com)
Shares of Bio-Techne Corp (NASDAQ TECH) traded up 1.49% during midday trading on Monday, hitting $121.76. 113,688 shares of the stock were exchanged. The firm has a 50 day moving average of $116.99 and a 200-day moving average of $110.19. Bio-Techne Corp has a 12 month low of $95.68 and a 12 month high of $121.94. The stock has a market cap of $4.55 billion, a P/E ratio of 59.11 and a beta of 0.79.
Bio-Techne Corp (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.10. The company had revenue of $156.60 million for the quarter, compared to analyst estimates of $150.25 million. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.18%. The business’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.92 earnings per share. Equities research analysts anticipate that Bio-Techne Corp will post $3.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 18th will be paid a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 16th. This represents a $1.28 dividend on an annualized basis and a yield of 1.05%. Bio-Techne Corp’s dividend payout ratio (DPR) is presently 65.98%.
A number of brokerages have issued reports on TECH. BidaskClub raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Wednesday, August 23rd. Zacks Investment Research lowered shares of Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Deutsche Bank AG raised their price target on shares of Bio-Techne Corp from $130.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Wells Fargo & Company began coverage on shares of Bio-Techne Corp in a report on Thursday, July 13th. They issued a “market perform” rating on the stock. Finally, TheStreet raised shares of Bio-Techne Corp from a “c+” rating to a “b” rating in a report on Tuesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Bio-Techne Corp currently has an average rating of “Buy” and a consensus target price of $127.50.
COPYRIGHT VIOLATION WARNING: “Bio-Techne Corp (TECH) Getting Somewhat Favorable Press Coverage, Analysis Finds” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/28/bio-techne-corp-tech-getting-somewhat-favorable-press-coverage-analysis-finds.html.
In other Bio-Techne Corp news, Director Charles A. Dinarello sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $111.37, for a total transaction of $556,850.00. Following the sale, the director now directly owns 12,473 shares in the company, valued at $1,389,118.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 5,300 shares of company stock worth $591,328 over the last quarter. Insiders own 2.70% of the company’s stock.
About Bio-Techne Corp
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.